Eicosapentaenoic acid role in preventing periprocedural (Type IVa) myocardial infarction in patients undergoing percutaneous coronary intervention

Trial Profile

Eicosapentaenoic acid role in preventing periprocedural (Type IVa) myocardial infarction in patients undergoing percutaneous coronary intervention

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Eicosapentaenoic acid (Primary) ; HMG-CoA reductase inhibitors
  • Indications Myocardial infarction
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top